Body Mass Index and Waistline Are Predictors of Survival for Hepatocellular Carcinoma After Hepatectomy

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2015 Jul 30

PMID 26223028

Citations 3

Authors

Xiyu Liu

Jiangfeng Xu

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide especially in China. This article aimed to evaluate the influence of body mass index (BMI) and waistline on complications, postoperative death, and long-term survival in patients undergoing surgery for HCC.

Material And Methods: 136 patients were enrolled and divided into 4 groups: group A, BMI <25; group B, BMI ≥25; group C, waistline <90 cm in males or waistline <80 cm in females; group D, waistline ≥90 cm in males or waistline ≥80 cm in females. Clinical pathological features and surgical outcomes of these patients were analyzed retrospectively.

Results: There were no significant differences in postoperative complication rate and postoperative death between group A and group B, although pulmonary infection showed a significant difference between 2 groups (P=0.017). Vascular invasion, waistline, and BMI are the independent prognostic factors for long-term survival. The disease-free survival curves after hepatectomy showed no statistically significant difference between group A and group B. Group C had the better overall survival than group D, and group A had the better overall survival than group B.

Conclusions: BMI and waistline are both independent prognostic factors for long-term survival of HCC after hepatectomy. Waistline is more important than BMI in predicting the disease-free survival of HCC after hepatectomy.

Citing Articles

Machine Learning Prognostic Model for Post-Radical Resection Hepatocellular Carcinoma in Hepatitis B Patients.

Zhu D, Tulahong A, Abuduhelili A, Liu C, Aierken A, Lin Y J Hepatocell Carcinoma. 2025; 12:353-365.

PMID: 39991515 PMC: 11847427. DOI: 10.2147/JHC.S495059.

The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies.

Lysaght J, Conroy M Nat Rev Endocrinol. 2024; 20(12):701-714.

PMID: 39313571 DOI: 10.1038/s41574-024-01032-5.

Adiposity and cancer survival: a systematic review and meta-analysis.

Cheng E, Kirley J, Cespedes Feliciano E, Caan B Cancer Causes Control. 2022; 33(10):1219-1246.

PMID: 35971021 PMC: 10101770. DOI: 10.1007/s10552-022-01613-7.

Are Metabolic Signatures Mediating the Relationship between Lifestyle Factors and Hepatocellular Carcinoma Risk? Results from a Nested Case-Control Study in EPIC.

Assi N, Thomas D, Leitzmann M, Stepien M, Chajes V, Philip T Cancer Epidemiol Biomarkers Prev. 2018; 27(5):531-540.

PMID: 29563134 PMC: 7444360. DOI: 10.1158/1055-9965.EPI-17-0649.

References

Mirza M . Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011; 2011:592404. PMC: 3168494. DOI: 10.5402/2011/592404. View

Loomba R, Ghany M . Association between body mass index and diabetes and hepatocellular carcinoma. Ann Intern Med. 2008; 148(2):166-7. DOI: 10.7326/0003-4819-148-2-200801150-00016. View

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

Maluccio M, Covey A . Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 2012; 62(6):394-9. DOI: 10.3322/caac.21161. View

Song H, Lee H, Lee J, Kim J, Yim Y, Song T . Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med. 2012; 27(1):47-52. PMC: 3295988. DOI: 10.3904/kjim.2012.27.1.47. View

Okamura Y, Maeda A, Matsunaga K, Kanemoto H, Uesaka K . Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2011; 19(4):449-57. DOI: 10.1007/s00534-011-0461-y. View

Liu B, Balkwill A, Reeves G, Beral V . Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. BMJ. 2010; 340:c912. PMC: 2837146. DOI: 10.1136/bmj.c912. View

Akiyama T, Mizuta T, Kawazoe S, Eguchi Y, Kawaguchi Y, Takahashi H . Body mass index is associated with age-at-onset of HCV-infected hepatocellular carcinoma patients. World J Gastroenterol. 2011; 17(7):914-21. PMC: 3051141. DOI: 10.3748/wjg.v17.i7.914. View

Day C . Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005; 129(1):375-8. DOI: 10.1053/j.gastro.2005.05.041. View

10.

Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Irani A . Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: a meta-analysis. PLoS One. 2012; 7(12):e51446. PMC: 3517558. DOI: 10.1371/journal.pone.0051446. View

11.

Garrisi V, Tufaro A, Trerotoli P, Bongarzone I, Quaranta M, Ventrella V . Body mass index and serum proteomic profile in breast cancer and healthy women: a prospective study. PLoS One. 2012; 7(11):e49631. PMC: 3511468. DOI: 10.1371/journal.pone.0049631. View

12.

Siegel A, Lim E, Wang S, Brubaker W, Rodriguez R, Goyal A . Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. Transplantation. 2012; 94(5):539-43. PMC: 3605709. DOI: 10.1097/TP.0b013e31825c58ea. View

13.

Sinicrope F, Foster N, Yothers G, Benson A, Seitz J, Labianca R . Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013; 119(8):1528-36. PMC: 3769640. DOI: 10.1002/cncr.27938. View

14.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

15.

Tsochatzis E, Meyer T, Burroughs A . Hepatocellular carcinoma. N Engl J Med. 2012; 366(1):92. DOI: 10.1056/NEJMc1112501. View

16.

Naveau S . Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study. Gastroenterol Clin Biol. 2010; 34(8-9):429-30. DOI: 10.1016/j.gcb.2010.05.003. View

17.

Serfaty L, Lemoine M . Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2009; 34(6 Pt 2):634-7. DOI: 10.1016/S1262-3636(08)74597-X. View

18.

Yeh J, Uemura M . Hepatocellular carcinoma. N Engl J Med. 2012; 366(1):92. DOI: 10.1056/NEJMc1112501. View

19.

El-Serag H . Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27. DOI: 10.1056/NEJMra1001683. View

20.

Maheshwari A, Thuluvath P . Cryptogenic cirrhosis and NAFLD: are they related?. Am J Gastroenterol. 2006; 101(3):664-8. DOI: 10.1111/j.1572-0241.2006.00478.x. View